Navigation Links
Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
Date:5/31/2008

Company Announces Winners of the 'It's Your Passion. Let It Out' Contest

ISTANBUL, Turkey, May 31 /PRNewswire/ -- Bayer HealthCare today announced the 20th anniversary of the company's Kogenate(R) line of products and more than two decades of hemophilia A research, collaboration and community building at the 2008 World Federation of Hemophilia (WFH) World Congress in Istanbul, Turkey. More than 8 billion international units of Kogenate(R) and Kogenate(R) FS/KOGENATE(R) Bayer have been infused to date.

Kogenate(R) clinical trials began in May 1988 in Bonn, Germany. This advent of recombinant factor VIII technology represented a leap forward in the delivery of safe, effective treatment for people with hemophilia A. Since then, Bayer's Kogenate(R) line of products has maintained a record of safety, with two decades of clinical use and no confirmed case of pathogen transmission.

"Besides celebrating an impressive 20 years of safe, effective treatment, we are celebrating the many lives that have been touched through the use of our Kogenate(R) line of products," said Michael E. Mathews, general manager, hemophilia, and vice president of marketing, specialty medicine, Bayer HealthCare. "We are passionate at Bayer about improving the lives of people living with hemophilia. We are the only company with a long-acting recombinant factor VIII protein in human clinical trials. We are also creating new and innovative delivery systems that decrease the discomfort of infusion and increase convenience."

To celebrate its 20-year milestone, Bayer launched the "It's Your Passion. Let It Out" contest. Applicants from around the world expressed -- in the medium of their choice -- what they are passionate about as members of the hemophilia community. Representatives of the WFH served as contest judges and chose three entries to receive the grand prize, an all-expense-paid trip for two to the 2008 WFH World Congress. The winners are:

-- Mindy
'/>"/>

SOURCE Bayer HealthCare
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
4. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
5. Thomson Healthcare Cancer Profiler Used in Study
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
10. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
11. Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2US Oncology Reports Second Quarter Operating Results 53858 1US Oncology Reports Second Quarter Operating Results 53858 2US Oncology Reports Second Quarter Operating Results 53858 3US Oncology Reports Second Quarter Operating Results 53858 4US Oncology Reports Second Quarter Operating Results 53858 5US Oncology Reports Second Quarter Operating Results 53858 6US Oncology Reports Second Quarter Operating Results 53858 7US Oncology Reports Second Quarter Operating Results 53858 8US Oncology Reports Second Quarter Operating Results 53858 9US Oncology Reports Second Quarter Operating Results 53858 10US Oncology Reports Second Quarter Operating Results 53858 11US Oncology Reports Second Quarter Operating Results 53858 12US Oncology Reports Second Quarter Operating Results 53858 13US Oncology Reports Second Quarter Operating Results 53858 14US Oncology Reports Second Quarter Operating Results 53858 15US Oncology Reports Second Quarter Operating Results 53858 16US Oncology Reports Second Quarter Operating Results 53858 17US Oncology Reports Second Quarter Operating Results 53858 18US Oncology Reports Second Quarter Operating Results 53858 19US Oncology Reports Second Quarter Operating Results 53858 20US Oncology Reports Second Quarter Operating Results 53858 21US Oncology Reports Second Quarter Operating Results 53858 22US Oncology Reports Second Quarter Operating Results 53858 23US Oncology Reports Second Quarter Operating Results 53858 24US Oncology Reports Second Quarter Operating Results 53858 25Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 1Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 2Efforts by Blue Cross Blue Shield of Michigan Physician Practices Help Michigan Become a Leading Adopter of E prescribing 53856 3BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 1BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 2BD Adds Surveillance Capability to Infectious Disease Portfolio 53851 3
...o, a division of Merck KGaA, Darmstadt, Germany, t... develop and commercialize Ambrx,s ARX424 preclini...e sclerosis. ARX424 was created by Ambrx through ...ation technology, ReCODE(TM). , , This second col...vious agreement announced in 2007 to develop ARX20...
...ceuticals, Inc. (Nasdaq: MAPP ) announced today ...nit Dose Budesonide (UDB) for the potential,treatm...d that the clinical,trial did not meet its co-prim...es from baseline in nighttime and daytime composit..., when compared with placebo. Median,nebulization...
Other Medicine Technology:Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 2Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance 3MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...CFS) has been associated with altered amounts of s...oencephalograph (EEG) activity and impaired sleep... journal SLEEP finds that CFS is also associated w...Roseanna Armitage, PhD, and colleagues at the Univ...
... not pose a risk of cancer; a Danish study conduct... has shown. Danish medical records were a... cancer, or brain cancer among the utility workers...bstantial evidence linking exposure to electro mag...
... have died in a hospital here in the month of Apri...ed from his post for not informing the state gove...s, however, put the number of infant deaths at the...sts conducted at the microbiology department of th...
...eed lift one out of depression. But its potential ...ognized . Now the U.S. Food and Drug Admin...tidepressant medications update the existing black...ring initial treatment, generally the first one to...
...Dakota is now infusing roasted sunflower seeds w...energy drinks , to provide players and other peopl... The product, which has been under developmen...e, lysine and ginseng are added. The 3.5-ounc...
...rchers, diabetes is fast becoming a common reason ...he Reproductive Medicine Research Group at Queen's... semen samples of 57 men who were diagnosed with D...such samples it was seen that diabetes brought abo...
Other Medicine News:Health News:Government Expels Superintendent for Not Informing Newborn Deaths 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 2Health News:FDA Advisory Against Anti-depressants to Be Expanded to Cover Young Adults too 3Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:Fertility Rates Felled By Diabetes 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: